Centauri Therapeutics Receives an Additional $5.1 M From CARB-X to Progress ABX-01 Lead Compound to First in Human Clinical Trials

Centauri Therapeutics receives an additional $5.1 M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

Centauri Therapeutics Limited ('Centauri'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1 M in funding for the development of their lead compound.

Centauri Therapeutics receives an additional $5.1M from CARB-X

Centauri, an immunotherapy company, announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1M in funding for the development of their lead compound.

Centauri Therapeutics Receives an Additional $5.1M from CARB-X to ...

CARB-X takes Centauri funding to £9.6m with latest investment

MedTech Centauri Therapeutics has received an extra £3.8m in funding from CARB-X to develop its lead antimicrobial drug. The latest cash boost will help move Centauri’s lead ABX-01 candidate into first-in-human clinical trials.  It also takes CARB-X’s investmnt into the company to £9.6m since 2019. Announced in March 2025, the candidate is a broad-spectrum antimicrobial – a drug that can kill or stop the growth of many different types of harmful…

Kinvard Bio Secures Follow-on CARB-X Funding to Accelerate Development of Next-Generation Antibiotics - PressReach

Open the article to view the coverage from pressreach.com

Biotech Centauri Therapeutics receives £3.8m follow-on funding

Cheshire-headquartered biotech company Centauri Therapeutics has received $5.1m (£3.8m) in funding to support the development of its lead compound. Based in Alderley Park, Centauri specialises in immunotherapy drug discovery and is currently working on the development of its ABX-01 programme, a broad-spectrum antimicrobial selected to combat clinically prevalent drug-resistant bacteria. In support of this, the Combating Antibiotic-Resistant Bact…